Developing a New Category of Drugs

Rebiotix is developing a new category of biologic drugs that use live human-derived organisms to treat disease.
Read more

The Troubling Rise in
C. diff. Infection

C. diff. infection is a growing and serious healthcare problem worldwide.
Read more

Recurrent C. diff: Unmet Medical Need

Currently, the only treatments available for patients with recurrent C. diff. infection are more antibiotics or surgery, both of which have serious limitations.
Read more

The Economic

C. diff. infection has recently been called an urgent public health threat by the US Centers for Disease Control.
Read more

New Ways to Treat Challenging  Diseases



Trillions of bacteria, viruses, and other microbes live in our bodies and work together to regulate processes critical to life including metabolism and the immune system. Collectively, the genetic material of these microbes forms the human microbiome.

The literal explosion of interest in the human microbiome has been sparked in part by the Human Microbiome Project, a 5-year effort sponsored by the US National Institutes of Health. The goal of the Human Microbiome Project was to characterize the microbial communities found at several different sites on the human body and to analyze the role of those microbes in human health and disease.

One of the focal points of the Human Microbiome Project was the human intestine. With its complex ecosystem and the most diverse microbes and the densest number of cells, the intestinal microbiome has continued to be a subject of intense research interest.

It is the goal of Rebiotix to harness the power of the microbiome to treat challenging gastrointestinal diseases by developing new biologic drugs.

Read More